MA51207A - Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation - Google Patents

Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation

Info

Publication number
MA51207A
MA51207A MA051207A MA51207A MA51207A MA 51207 A MA51207 A MA 51207A MA 051207 A MA051207 A MA 051207A MA 51207 A MA51207 A MA 51207A MA 51207 A MA51207 A MA 51207A
Authority
MA
Morocco
Prior art keywords
methods
monoclonal antibodies
trkb monoclonal
trkb
antibodies
Prior art date
Application number
MA051207A
Other languages
English (en)
Inventor
Susan D Croll
Min Gao
Ying Hu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA51207A publication Critical patent/MA51207A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA051207A 2017-11-30 2018-11-28 Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation MA51207A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762592657P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
MA51207A true MA51207A (fr) 2020-10-07

Family

ID=64665125

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051207A MA51207A (fr) 2017-11-30 2018-11-28 Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation

Country Status (18)

Country Link
US (3) US11066474B2 (fr)
EP (1) EP3717514A1 (fr)
JP (2) JP7438937B2 (fr)
KR (1) KR20200090779A (fr)
CN (2) CN111372949B (fr)
AU (3) AU2018375340B2 (fr)
BR (1) BR112020006976A2 (fr)
CA (1) CA3083452A1 (fr)
CL (3) CL2020000855A1 (fr)
CO (1) CO2020004075A2 (fr)
EA (1) EA202090966A1 (fr)
IL (1) IL273538B2 (fr)
MA (1) MA51207A (fr)
MX (3) MX2020003550A (fr)
MY (1) MY203247A (fr)
PH (1) PH12020550409A1 (fr)
SG (1) SG11202002665UA (fr)
WO (1) WO2019108662A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
EP3717514A1 (fr) * 2017-11-30 2020-10-07 Regeneron Pharmaceuticals, Inc. Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation
IL274740B2 (en) * 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
CN113557301B (zh) * 2019-03-04 2025-03-07 公益财团法人东京都医学综合研究所 编码Trk片段的核酸构建体及其利用
WO2021155141A1 (fr) * 2020-01-30 2021-08-05 Fred Hutchinson Cancer Research Center Compositions à base d'anticorps pour le ciblage d'isoformes du récepteur kinase b de la tropomyosine (trkb)
WO2023125485A1 (fr) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited Anticorps trkb et son application
EP4501941A1 (fr) 2022-03-30 2025-02-05 PeptiDream Inc. Complexe peptidique ayant une activité de liaison trkb

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6225282B1 (en) 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GT200600240A (es) 2005-06-06 2007-03-14 Anticuerpos monoclonales anti-trkb y usos de los mismos
EP1988923A1 (fr) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Procédés de traitement de perte de poids non recherchée ou de troubles de l'alimentation par administration d'un agoniste trkb
US7935342B2 (en) 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
CA2669205A1 (fr) 2006-11-09 2008-05-15 Irm Llc Anticorps d'agonistes de trkb et leurs utilisations
BRPI0720473A2 (pt) * 2006-12-20 2014-01-14 Rinat Neuroscience Corp Agonistas de trkb para tratamento de distúbios autoimunes
CA2701189C (fr) 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methodes permettant de traiter la neuropathie optique induite par la pression, de prevenir la degenerescence des neurones et de favoriser la survie des neurones par l'administration d'antagonistes de lingo-1 et d'agonistes de trkb
CN102015769B (zh) 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
WO2011103667A1 (fr) 2010-02-26 2011-09-01 6452728 Canada Inc. Anticorps agonistes des récepteurs trkb et leurs utilisations
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
WO2015077672A1 (fr) 2013-11-25 2015-05-28 The Regents Of The University Of California Santa Cruz Inhibiteurs de croissance bactérienne a base de piéricidine
JP6868394B2 (ja) 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
BR112018001900A2 (pt) 2015-07-28 2018-09-18 Otonomy, Inc. composições agonistas de trkb ou trkc e métodos para o tratamento de condições óticas
TW201730206A (zh) 2015-11-17 2017-09-01 葛蘭素史克智慧財產發展有限公司 用於治療神經及其他疾病之結合激動劑
JP2019517787A (ja) * 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP3596126A4 (fr) * 2017-03-15 2021-03-03 Tsinghua University Nouveaux anticorps anti-trkb
EP3717514A1 (fr) * 2017-11-30 2020-10-07 Regeneron Pharmaceuticals, Inc. Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3717514A1 (fr) 2020-10-07
US20190161551A1 (en) 2019-05-30
US20220411515A1 (en) 2022-12-29
AU2026200616A1 (en) 2026-02-19
CL2024002612A1 (es) 2025-01-24
JP2021507677A (ja) 2021-02-25
IL273538B2 (en) 2024-10-01
AU2018375340B2 (en) 2025-10-30
IL273538A (en) 2020-05-31
CL2020000855A1 (es) 2020-07-31
CN121181700A (zh) 2025-12-23
CO2020004075A2 (es) 2020-08-31
WO2019108662A1 (fr) 2019-06-06
CA3083452A1 (fr) 2019-06-06
NZ763618A (en) 2025-05-02
AU2018375340A1 (en) 2020-05-07
MX2025001445A (es) 2025-03-07
US20240309100A1 (en) 2024-09-19
JP2024016204A (ja) 2024-02-06
PH12020550409A1 (en) 2021-04-12
KR20200090779A (ko) 2020-07-29
EA202090966A1 (ru) 2020-08-26
MX2025001444A (es) 2025-03-07
AU2026200583A1 (en) 2026-02-19
JP7438937B2 (ja) 2024-02-27
US12037401B2 (en) 2024-07-16
CN111372949A (zh) 2020-07-03
BR112020006976A2 (pt) 2020-10-13
CL2024002614A1 (es) 2025-01-24
CN111372949B (zh) 2026-02-03
US11066474B2 (en) 2021-07-20
MX2020003550A (es) 2020-08-03
IL273538B1 (en) 2024-06-01
MY203247A (en) 2024-06-19
SG11202002665UA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
FR24C1050I1 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3797123A4 (fr) Anticorps anti-ox40 et procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3472316A4 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3491025A4 (fr) Anticorps fcrn et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA43658A (fr) Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA47691A (fr) Anticorps anti-cd33 et leurs procédés d'utilisation
EP3684821A4 (fr) Anticorps anti-hla-a2 et leurs procédés d'utilisation